© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Expert Interviews
Exploring Non-Pharmacologic Treatment Options for Patients With Dry Eye Disease
June 28, 2022
Various treatments for dry eye disease are navigated with regard to both payer and provider considerations.
Identifying Drivers of Economic Burden Associated With Dry Eye Disease
June 21, 2022
Dr Periman addresses cost-related concerns associated with treating dry eye disease.
Impact of Dry Eye Disease on Quality of Life
June 14, 2022
Quality-of-life concerns, including biopsychosocial impacts caused by dry eye disease, are explored by Dr Periman.
Pathology and Prevalence of Dry Eye Disease
June 07, 2022
Dr Laura Periman, MD illustrates the current risk factors and prevalence regarding patients with dry eye disease.
Prescribing AD Therapy: What to Consider
May 31, 2022
Dr Bhatia concludes our discussion by outlining what factors physicians should be cognizant of when prescribing therapies to patients with AD.
The Impact of JAK Inhibitors in AD Treatment
May 31, 2022
A dermatology expert highlights the role JAK inhibitors play in AD therapy, from mechanism of action to ruxolitinib and the TrUE AD1 and -2 trials.
Navigating the AD Treatment Landscape
May 20, 2022
Dr Neal Bhatia explains the available treatment options for patients with AD, including their relation to guideline recommendations.
Diagnosing Severe Atopic Dermatitis
May 20, 2022
Neal Bhatia, MD, provides an overview of atopic dermatitis (AD) and the diagnostic process, as well as how its severity impacts the patient.
Individualizing UF Therapy
May 06, 2022
Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.
Addressing Unmet Needs in UF
May 06, 2022
Dr Al-Hendy discusses what it takes to individualize UF treatment for each patient.